
I remember Marc Garneau
The Stars and Stripes on the flagpole at the front of the Johnson Space Center is enormous, as you'd expect from a major American institution.
I had been at Johnson for a couple of days, as a reporter covering the shuttle flight of Canadian astronaut Steve MacLean, and I remember being struck by the sheer size of the place – some 100 buildings on more than 1,600 acres of land.
And, of course, that giant, brash flag.
I first met Marc Garneau, Canada's first astronaut, on Oct. 24, 1992, at JSC, where he was with the Canadian Space Agency. MacLean's shuttle had been launched from Kennedy Space Center two days earlier and I had flown across the U.S. to follow the flight from mission control at JSC.
Marc Garneau, first Canadian in space, remembered for aspirations he held for his country
That Saturday evening, there was also some baseball being played.
The Toronto Blue Jays, leading the World Series with the Atlanta Braves 3-2, were in the Georgia city for Game 6. After filing my report for the day to the Toronto Star, I joined other journalists and members of the Canadian Space Agency in a hotel room to watch the game.
Garneau, as I recall, was not expected, owing to pressure of work on the mission, but showed up anyway, a couple of innings into the game. Someone had organized a betting pool, in which you picked a number. If that number turned out to equal the sum of the runs scored in the game, you took the kitty.
As it happened, both Garneau and I had 7; the Jays won the game 4-3 to take their first World Series so Garneau and I shared the small prize.
The party broke up soon after the game ended. The shuttle mission was still under way and we all had work the next day.
That Sunday, as I drove into the JSC complex, I noticed an oddity.
Atop the flagpole, above the U.S. flag, was a small red and white banner. Somehow, the Maple Leaf had been hoisted during the night. And because it was Sunday, with only the shuttle mission staff on the premises, it stayed there all day.
When it comes to space, Canada has always reached for the stars
I met Garneau a couple of times later, in the course of my work as The Star's science reporter, and asked him about the flag.
He said he couldn't possibly comment.
You can find more obituaries from The Globe and Mail here.
To submit a memory about someone we have recently profiled on the Obituaries page, e-mail us at obit@globeandmail.com.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Globe and Mail
2 hours ago
- Globe and Mail
Traumatic Brain Injury Pipeline Appears Robust With 20+ Key Pharma Companies Actively Working in the Therapeutics Segment
DelveInsight's ' Traumatic Brain Injury Pipeline Insight 2025 ' report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in Tthe raumatic Brain Injury pipeline landscape. It covers the Traumatic Brain Injury pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Traumatic Brain Injury pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Explore the comprehensive insights by DelveInsight and stay ahead in understanding the Traumatic Brain Injury Treatment Landscape. Click here to read more @ Traumatic Brain Injury Pipeline Outlook Key Takeaways from the Traumatic Brain Injury Pipeline Report In June 2025, Hope Biosciences announced a study is to establish the safety and investigate the potential treatment effect of an intravenous infusion of HB-adMSCs (Hope Biosciences adipose-derived mesenchymal stem cells) on brain structure, neurocognitive/functional outcomes, and neuroinflammation after traumatic brain injury. In June 2025, Merz Pharmaceuticals GmbH conducted a study is to determine whether a single treatment with administration of 400 Units NT 201 (botulinum toxin) is superior to placebo (no medicine) for the treatment of lower limb spasticity caused by stroke or traumatic brain injury (Main Period). Participants will be assigned to the treatment groups by chance and neither the participants nor the research staff who interact with them will know the allocation. In June 2025, Ipsen organized a study is to assess the safety and efficacy of increasing doses of IPN10200 with the aim to evaluate the Pharmacodynamics (PD) profile of IPN10200 and to establish the total IPN10200 doses(s) that offer the best efficacy/safety profile when used for the treatment of Adult upper limb (AUL) spasticity. DelveInsight's Traumatic Brain Injury pipeline report depicts a robust space with 20+ active players working to develop 22+ pipeline therapies for Traumatic Brain Injury treatment. The leading Traumatic Brain Injury Companies such as Oragenics, Inc, SHINKEI Therapeutics, Inc, AlzeCure, Algernon Pharmaceutical, Mitochon Pharmaceuticals, Hoth Therapeutics, Biomed Industries, Inc, BioArctic, Tiziana Life Sciences, TikoMed AB, Levolta Pharmaceuticals, Inc, Boulder BioScience, LLC, International Stem Cell Corporation, Revalesio Corporation, Teleport Pharmaceuticals and others. Promising Traumatic Brain Injury Pipeline Therapies such as Flortaucipir F18, NE3107, Amantadine Hydrochloride, VAS203, SB623 cells, Rivastigmine, VAS203, Dexanabinol and others. Discover groundbreaking developments in Traumatic Brain Injury Therapies! Gain in-depth knowledge of key Traumatic Brain Injury Emerging Drugs, and market opportunities @ Traumatic Brain Injury Clinical Trials Assessment Traumatic Brain Injury Emerging Drugs Profile ONP-002: Oragenics, Inc. ONP-002 is a First-in-Class Enantiomeric-Neurosteroid being developed for the treatment of mild Traumatic Brain Injury (mTBI) aka concussion. ONP-002 diffuses intracellularly to induce steroid receptors found in neurons, glia, and the endothelium of the blood brain-barrier. The induction of the ONP-002 receptors activates multiple gene response elements leading to the production of mRNA transcripts and subsequently proteins that reduce inflammation, oxidative stress, and swelling. In addition, ONP-002 induces macro-autophagy to reduce the build-up of extra- and intra-cellular debris that can cause chronic neurological diseases associated with dementia. Currently, the drug is in the Phase II stage of its development for the treatment of Traumatic Brain Injury. MR-301: SHINKEI Therapeutics, Inc MR-301 – Amantadine HCl Intravenous (IV) Solution is SHINKEI's most advanced program. Amantadine HCl is one of the most commonly prescribed off-label medications for patients with prolonged disorders of consciousness after TBI. Amantadine HCl increases dopamine availability in the synapse by inhibiting the activation of dopaminergic receptors. Amantadine HCl has been approved as a prescription oral product in the U.S since 1966 and, as such, has a long history of safe use in the U.S. and globally. Preliminary studies in preclinical models and patients with TBI have suggested that amantadine may promote functional recovery with high levels of safety. Currently, the drug is in Phase II stage of its development for the treatment of Traumatic Brain Injury. ACD 856: AlzeCure ACD 856 is a small molecule, positive allosteric modulator of Trk receptors, which mediate the effects of BDNF, NGF, and other neurotrophic factors. ACD856 increases the kinase activity of Trk receptors and enhances the effects of BDNF or NGF on survival, neuronal function, and synaptic plasticity. This is intended to make up for loss of BDNF and NGF signaling that occurs in AD. This compound is taken orally. The compound improves mitochondrial function and increases BDNF expression in cells, and shows antidepressant activity in mice. Currently, the drug is in Phase I stage of its development for the treatment of Traumatic Brain Injury. AP-188: Algernon Pharmaceutical AP-188 (N,N-Dimethyltryptamine, or DMT) is a potential treatment for stroke and traumatic brain injury (TBI) recovery. DMT is a naturally occurring compound that is part of the tryptamine family, which also includes psilocybin and psilocin. DMT is naturally occurring and found in plants and animals and is expressed naturally in humans in times of great physiological stress, including cardiac arrest and childbirth. It is assumed to have roles in cell protection, regeneration, and immunity as well. The drug is a sigma receptor agonist, and some evidence points to sigma receptor binding as a critical factor in the drug's protective actions. Psychedelic drugs as a class have also demonstrated an ability to promote neuritogenesis both in vivo and in vitro. The effects are believed to be through agonism of the 5-HT2A receptor, although other receptors, including sigma, may be involved. DMT increases expression of Brain Derived Neurotropic Factor (BDNF), which promotes neuroplasticity: a key factor in the brain's ability to form and reorganize synaptic connections, which are needed for healing following a brain injury. DMT is also known to bind to a number of other receptors, including various 5-HT, dopamine, adrenergic, and trace amine receptors. Currently, the drug is in Phase I stage of its development for the treatment of Traumatic Brain Injury. The Traumatic Brain Injury Pipeline Report Provides Insights into The report provides detailed insights about companies that are developing therapies for the treatment of Traumatic Brain Injury with aggregate therapies developed by each company for the same. It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Traumatic Brain Injury Treatment. Traumatic Brain Injury Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. Traumatic Brain Injury Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Traumatic Brain Injury market Stay informed about the Traumatic Brain Injury pipeline trends! Uncover critical updates on therapeutic innovations and their potential impact on patients and the healthcare industry @ Traumatic Brain Injury Unmet Needs Traumatic Brain Injury Companies Oragenics, Inc, SHINKEI Therapeutics, Inc, AlzeCure, Algernon Pharmaceutical, Mitochon Pharmaceuticals, Hoth Therapeutics, Biomed Industries, Inc, BioArctic, Tiziana Life Sciences, TikoMed AB, Levolta Pharmaceuticals, Inc, Boulder BioScience, LLC, International Stem Cell Corporation, Revalesio Corporation, Teleport Pharmaceuticals and others. Traumatic Brain Injury pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as Oral Intravenous Subcutaneous Parenteral Topical Traumatic Brain Injury Products have been categorized under various Molecule types such as Recombinant fusion proteins Small molecule Monoclonal antibody Peptide Polymer Gene therapy Transform your understanding of the Traumatic Brain Injury Pipeline! See the latest progress in drug development and clinical research @ Traumatic Brain Injury Market Drivers and Barriers, and Future Perspectives Scope of the Traumatic Brain Injury Pipeline Report Coverage- Global Traumatic Brain Injury Companies- Oragenics, Inc, SHINKEI Therapeutics, Inc, AlzeCure, Algernon Pharmaceutical, Mitochon Pharmaceuticals, Hoth Therapeutics, Biomed Industries, Inc, BioArctic, Tiziana Life Sciences, TikoMed AB, Levolta Pharmaceuticals, Inc, Boulder BioScience, LLC, International Stem Cell Corporation, Revalesio Corporation, Teleport Pharmaceuticals and others. Traumatic Brain Injury Pipeline Therapies- Flortaucipir F18, NE3107, Amantadine Hydrochloride, VAS203, SB623 cells, Rivastigmine, VAS203, Dexanabinol and others. Traumatic Brain Injury Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination Traumatic Brain Injury Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Stay Ahead in Research-Access the Full Traumatic Brain Injury Pipeline Analysis Today! @ Traumatic Brain Injury Drugs and Companies Table of Contents Introduction Executive Summary Traumatic Brain Injury: Overview Pipeline Therapeutics Therapeutic Assessment Traumatic Brain Injury– DelveInsight's Analytical Perspective Late Stage Products (Phase III) Drug Name: Company Name Drug profiles in the detailed report….. Mid Stage Products (Phase II) ONP-002: Oragenics, Inc. Drug profiles in the detailed report….. Early Stage Products (Phase I) ACD 856: AlzeCure Drug profiles in the detailed report….. Preclinical and Discovery Stage Products Drug Name: Company Name Drug profiles in the detailed report….. Inactive Products Traumatic Brain Injury Key Companies Traumatic Brain Injury Key Products Traumatic Brain Injury- Unmet Needs Traumatic Brain Injury- Market Drivers and Barriers Traumatic Brain Injury- Future Perspectives and Conclusion Traumatic Brain Injury Analyst Views Traumatic Brain Injury Key Companies Appendix About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Yash Bhardwaj Email: Send Email Phone: 09650213330 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:


CBC
5 hours ago
- CBC
Small Cape Breton school gets kudos for big environmental efforts
A small Cape Breton school is getting national recognition for its environmental efforts. The Donkin School is the only school in Nova Scotia to receive eco-certification at the platinum level from EcoSchools Canada, a non-profit group focused on building sustainable communities. The school has about 130 students ranging from pre-primary to Grade 8 and has undertaken many initiatives including community cleanups and energy conservation days. "We turned off the lights for a day," said Grade 8 student Lukas Burke. "It was sweater day, for like turning down the heat." The students have also been working in a community garden on the school's grounds. They planted tomatoes, strawberries, carrots and some trees, including plum, apple and peach trees. The school also participated in an event called the Great Gulp to raise awareness about access to clean water on World Water Day. People could enter the competition by drinking tap water from a reusable water bottle and sharing a picture of themselves drinking it. The school invited a Mi'kmaw elder for a traditional Grandmother Moon ceremony, which included a blessing of the water and teaching students the source of the water and the importance of having access to clean water. Math and science teacher Brittney Melnick said she is proud of her school's efforts and is thrilled the school is being recognized. She said the school plans to continue to find new ways to be eco-friendly. "Hard work, dedication and finally achieving something that we have been really working toward at the school," said Melnick of the certification. "We are excited to see what opportunities this gives us in the coming years."


Globe and Mail
8 hours ago
- Globe and Mail
Clene (NASDAQ: CLNN) Advances Regulatory Strategy for CNM-Au8 with FDA Meetings Scheduled for ALS and MS Programs
Clene (NASDAQ: CLNN) announced key regulatory developments following a Type C meeting with the FDA, where it received feedback on its statistical analysis plan (SAP) for evaluating neurofilament light (NfL) biomarker data from its Expanded Access Protocol for ALS. The company has resubmitted a revised SAP and anticipates FDA acceptance this summer, with NfL analyses scheduled for early Q4 2025 to support a potential NDA submission under the accelerated approval pathway. Clene also confirmed two additional FDA meetings in Q3 2025: one to assess long-term ALS survival data for accelerated approval consideration and another End-of-Phase 2 Type B meeting to review Phase 2 MS trial results and discuss a Phase 3 study targeting cognitive improvement. To view the full press release, visit About Clene Inc. Clene (along with its subsidiaries, 'Clene') and its wholly owned subsidiary Clene Nanomedicine Inc., is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis, Parkinson's disease and multiple sclerosis. CNM-Au8® is an investigational first-in-class therapy that improves central nervous system cells' survival and function via a mechanism that targets mitochondrial function and the NAD pathway while reducing oxidative stress. CNM-Au8® is a federally registered trademark of Clene Nanomedicine, Inc. The company is based in Salt Lake City, Utah, with R&D and manufacturing operations in Maryland. For more information, please visit About BioMedWire BioMedWire ('BMW') is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today's market, BMW brings its clients unparalleled recognition and brand awareness. BMW is where breaking news, insightful content and actionable information converge. To receive SMS alerts from BioMedWire, 'Biotech' to 888-902-4192 (U.S. Mobile Phones Only) For more information, please visit Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: BioMedWire Austin, Texas 512.354.7000 Office Editor@ BioMedWire is powered by IBN